Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post-Marketing Surveillance Study
Author:
Affiliation:
1. Lilly Korea, Seoul, South Korea.
2. Lilly Suzhou Pharmaceutical Company, Shanghai, China.
3. Department of Urology, Pusan National University School of Medicine, Busan, Korea.
4. Eli Lilly de Mexico, Mexico City, Mexico.
Funder
Eli Lilly and Company
Publisher
Korean Society for Sexual Medicine and Andrology
Subject
Pharmacology (medical),Urology,Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Health Policy,Aging,Reproductive Medicine
Link
https://synapse.koreamed.org/pdf/10.5534/wjmh.17017
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Discontinuation Rates of Tadalafil Alone and in Combination with a-Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis;International Journal of Clinical Practice;2022-11-03
2. EFFECTS OF GANODERMA LUCIDUM TRITERPENOIDS ON MITOCHONDRIAL APOPTOSIS FACTORS IN MICE WITH PROSTATIC HYPERPLASIA INDUCED BY TESTOSTERONE PROPIONATE;ACTA MEDICA MEDITERR;2022
3. EFFECT OF IL-2 ON PROLIFERATION AND APOPTOSIS OF PROSTATIC HYPERPLASIA EPITHELIAL CELLS VIA THE ERK1/2 SIGNALING PATHWAY;ACTA MEDICA MEDITERR;2022
4. Tea Marketing Strategy Based on Big Data;2021 International Conference on Applications and Techniques in Cyber Intelligence;2021
5. Real-World Safety and Effectiveness of Tadalafil in Patients with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Japanese Post-Marketing Surveillance Study;Pragmatic and Observational Research;2020-05
Real-World Safety and Effectiveness of Tadalafil in Patients with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Japanese Post-Marketing Surveillance Study
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3